Literature DB >> 21267730

[Methotrexate toxicity. Myths and facts].

G Keysser1.   

Abstract

Methotrexate (MTX) is a safe and well-tolerated drug for the treatment of rheumatic diseases, even if the strictest safety standards are considered. Initial apprehension as to severe pulmonary or hepatic side-effects has not been confirmed. The risk of infection is not elevated compared with other disease-modifying antirheumatic drugs. In addition, a mutagenic potential could not be demonstrated even after long-term application. Therefore, MTX will maintain its significant role in antirheumatic therapy also in the near future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21267730     DOI: 10.1007/s00393-010-0687-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  51 in total

Review 1.  Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

Authors:  Deborah P M Symmons; Alan J Silman
Journal:  Arthritis Rheum       Date:  2004-06

2.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

3.  The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.

Authors:  Z Ortiz; B Shea; M E Suarez-Almazor; D Moher; G A Wells; P Tugwell
Journal:  J Rheumatol       Date:  1998-01       Impact factor: 4.666

4.  Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests.

Authors:  J K Dawson; D R Graham; J Desmond; H E Fewins; M P Lynch
Journal:  Rheumatology (Oxford)       Date:  2002-03       Impact factor: 7.580

5.  Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.

Authors:  O Elkayam; M Yaron; G Zhukovsky; R Segal; D Caspi
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

6.  Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.

Authors:  Peter D Kent; Harvinder S Luthra; Clement Michet
Journal:  J Rheumatol       Date:  2004-09       Impact factor: 4.666

7.  Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.

Authors:  Y Yazici; T Sokka; H Kautiainen; C Swearingen; I Kulman; T Pincus
Journal:  Ann Rheum Dis       Date:  2004-06-18       Impact factor: 19.103

8.  Liver ultrastructure in psoriatics related to methotrexate therapy. 2. Findings in bile ducts from 11 methotrexate treated psoriatics and 2 controls.

Authors:  D Hopwood; A Nyfors
Journal:  Acta Pathol Microbiol Scand A       Date:  1977-11

Review 9.  An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.

Authors:  Eric N van Roon; Patricia M L A van den Bemt; Tim L Th A Jansen; Nella M Houtman; Mart A F J van de Laar; Jacobus R B J Brouwers
Journal:  Clin Ther       Date:  2009-08       Impact factor: 3.393

10.  Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX.

Authors:  S L Hider; W Thomson; L F Mack; D J Armstrong; M Shadforth; I N Bruce
Journal:  Rheumatology (Oxford)       Date:  2008-06-06       Impact factor: 7.580

View more
  4 in total

Review 1.  [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus].

Authors:  M Aringer; N Leuchten; R Fischer-Betz
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

2.  [Differential diagnosis of elevated liver transaminases in rheumatic diseases].

Authors:  W-J Mayet
Journal:  Z Rheumatol       Date:  2015-03       Impact factor: 1.372

3.  Drug induced interstitial lung disease.

Authors:  Martin Schwaiblmair; Werner Behr; Thomas Haeckel; Bruno Märkl; Wolfgang Foerg; Thomas Berghaus
Journal:  Open Respir Med J       Date:  2012-07-27

4.  Transporter-mediated interaction of indican and methotrexate in rats.

Authors:  Shiuan-Pey Lin; Chung-Ping Yu; Yu-Chi Hou; Ching-Ya Huang; Lu-Ching Ho; Shu-Ling Chan
Journal:  J Food Drug Anal       Date:  2017-12-14       Impact factor: 6.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.